Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.
Prasad R, Rehman A, Rehman L, Darbaniyan F, Blumenberg V, Schubert ML, Mor U, Zamir E, Schmidt S, Hayase T, Chia-Chi C, McDaniel LK, Flores I, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Wang ML, Jain P, Nastoupil LJ, Westin JR, Arora R, Turner JG, Khawaja F, Wu R, Dennison JB, Menges M, Hidalgo-Vargas M, Reid KM, Davila ML, Dreger P, Korell F, Schmitt A, Tanner MR, Champlin RE, Flowers CR, Shpall EJ, Hanash S, Neelapu SS, Schmitt M, Subklewe M, Fahrmann J, Stein-Thoeringer C, Elinav E, Jain MD, Hayase E, Jenq RR, Saini NY. Prasad R, et al. Among authors: darbaniyan f. Blood. 2024 Oct 23:blood.2024025366. doi: 10.1182/blood.2024025366. Online ahead of print. Blood. 2024. PMID: 39441941
MicroRNAs are enriched at COVID-19 genomic risk regions, and their blood levels correlate with the COVID-19 prognosis of cancer patients infected by SARS-CoV-2.
Anfossi S, Darbaniyan F, Quinlan J, Calin S, Shimizu M, Chen M, Rausseo P, Winters M, Bogatenkova E, Do KA, Martinez I, Li Z, Antal L, Olariu TR, Wistuba I, Calin GA. Anfossi S, et al. Among authors: darbaniyan f. Mol Cancer. 2024 Oct 21;23(1):235. doi: 10.1186/s12943-024-02094-9. Mol Cancer. 2024. PMID: 39434078 Free PMC article.
Downregulation of UBA1 expression in myelodysplastic neoplasm.
Wei Y, Zheng H, Li Z, Lockyer PP, Darbaniyan F, Kanagal-Shamanna R, Yang H, Hammond D, Garcia-Manero G. Wei Y, et al. Among authors: darbaniyan f. Leukemia. 2024 Oct;38(10):2284-2288. doi: 10.1038/s41375-024-02364-x. Epub 2024 Aug 23. Leukemia. 2024. PMID: 39179668 Free PMC article. No abstract available.
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.
Montalban-Bravo G, Thongon N, Rodriguez-Sevilla JJ, Ma F, Ganan-Gomez I, Yang H, Kim YJ, Adema V, Wildeman B, Tanaka T, Darbaniyan F, Al-Atrash G, Dwyer K, Loghavi S, Kanagal-Shamanna R, Song X, Zhang J, Takahashi K, Kantarjian H, Garcia-Manero G, Colla S. Montalban-Bravo G, et al. Among authors: darbaniyan f. Cell Rep Med. 2024 Jun 18;5(6):101585. doi: 10.1016/j.xcrm.2024.101585. Epub 2024 May 22. Cell Rep Med. 2024. PMID: 38781960 Free PMC article.
Clonal dominance defines metastatic dissemination in pancreatic cancer.
Ho IL, Li CY, Wang F, Zhao L, Liu J, Yen EY, Dyke CA, Shah R, Liu Z, Çetin AO, Chu Y, Citron F, Attanasio S, Corti D, Darbaniyan F, Del Poggetto E, Loponte S, Liu J, Soeung M, Chen Z, Jiang S, Jiang H, Inoue A, Gao S, Deem A, Feng N, Ying H, Kim M, Giuliani V, Genovese G, Zhang J, Futreal A, Maitra A, Heffernan T, Wang L, Do KA, Gargiulo G, Draetta G, Carugo A, Lin R, Viale A. Ho IL, et al. Among authors: darbaniyan f. Sci Adv. 2024 Mar 15;10(11):eadd9342. doi: 10.1126/sciadv.add9342. Epub 2024 Mar 13. Sci Adv. 2024. PMID: 38478609 Free article.
Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS -mutated chronic myelomonocytic leukemia.
Montalban-Bravo G, Ma F, Thongon N, Yang H, Gomez IG, Rodriguez-Sevilla JJ, Adema V, Wildeman B, Lockyer P, Kim YJ, Tanaka T, Darbaniyan F, Pancholy S, Zhang G, Al-Atrash G, Dwyer K, Takahashi K, Garcia-Manero G, Kantarjian H, Colla S. Montalban-Bravo G, et al. Among authors: darbaniyan f. bioRxiv [Preprint]. 2023 Apr 8:2023.04.07.535928. doi: 10.1101/2023.04.07.535928. bioRxiv. 2023. Update in: Cell Rep Med. 2024 Jun 18;5(6):101585. doi: 10.1016/j.xcrm.2024.101585 PMID: 37066354 Free PMC article. Updated. Preprint.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Bazinet A, et al. Among authors: darbaniyan f. Cancer. 2023 Feb 15;129(4):560-568. doi: 10.1002/cncr.34564. Epub 2022 Dec 2. Cancer. 2023. PMID: 36458426 Free article.
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS.
Sasaki K, Jabbour E, Montalban-Bravo G, Darbaniyan F, Do KA, Class C, Short NJ, Kanagal-Shamana R, Kadia T, Borthakur G, Pemmaraju N, Cortes J, Ravandi F, Alvarado Y, Chien K, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Soltysiak K, Yang H, Kantarjian HM, Garcia-Manero G. Sasaki K, et al. Among authors: darbaniyan f. NEJM Evid. 2022 Oct;1(10):EVIDoa2200034. doi: 10.1056/EVIDoa2200034. Epub 2022 Aug 9. NEJM Evid. 2022. PMID: 38319837 Clinical Trial.
Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
Darbaniyan F, Zheng H, Kanagal-Shamanna R, Lockyer P, Montalban-Bravo G, Estecio M, Lu Y, Soltysiak KA, Chien KS, Yang H, Sasaki K, Class C, Ganan-Gomez I, Do KA, Garcia-Manero G, Wei Y. Darbaniyan F, et al. Exp Hematol. 2022 Nov;115:44-53. doi: 10.1016/j.exphem.2022.09.002. Epub 2022 Sep 21. Exp Hematol. 2022. PMID: 36150563 Free article.
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Bazinet A, et al. Among authors: darbaniyan f. Lancet Haematol. 2022 Oct;9(10):e756-e765. doi: 10.1016/S2352-3026(22)00216-2. Epub 2022 Sep 2. Lancet Haematol. 2022. PMID: 36063832 Clinical Trial.
18 results